Monocyte counts have previously been associated with CTC levels in MBC patients [25] and high levels of CD14+HLA-DR+ monocytes associated with improved breast-cancer-specific survival in MBC patients treated with high-dose chemotherapy [27]. The gene discussed is CD14; the disease is breast carcinoma.